The more political insider is exposed, it is hard for the people in Taiwan to trust their own vaccines
[Global Times Special Correspondent Cheng Dong] Taiwan Union Asia announced its Phase II clinical trial data of the new crown vaccine, claiming to be resistant to the delta mutant virus, but the low neutralizing antibody titer makes it difficult for the island to feel at ease anyway.
According to Taiwan’s "United Daily News" reported on the 28th, the Phase II clinical data of Lianya Biotech's new crown vaccine was released on 27th, showing that the vaccine is safe and well tolerated, and all subjects have no serious adverse reactions related to the vaccine.
In terms of immunogenicity, the seroconversion rate of antibody titer at 28 days after the second injection was 95.65% in the adult (19 to 64 years old) group, and 88.57% in the elderly (over 65 years old) group. The neutralizing antibody titer is 102.3; from the comprehensive antibody experiment of mutated viruses in various places, the immune response can be anti-Delta virus.
Peng Wenjun, Chief Operating Officer of Uniasia Biotechnology, said that the data released by Uniasia this time belong to the second phase of clinical interim analysis, not to solve blindness. There are only two results of "safety and tolerability" and "immunogenesis", and there is no outside concern. The company will collect clinical data before the end of June and send it to the “Food and Drug Administration” to apply for an emergency authorization (EUA), and “the real phase 2 trial will be unblinded, and the time point will be in November.”
Peng Wenjun also revealed that Lianya plans to conduct a Phase III clinical trial with a scale of about 11,000 people in India, and data on the protective power will be visible by then.
As for the high-end vaccine, some Taiwanese media disclosed on the 28th that although it announced the results of the second phase of the analysis on June 10, it was required to make a supplement due to incomplete data submitted for review.
"Director of Food and Drug Administration" Wu Xiumei said that the high-end may not have a way to review the EUA until the end of July.
Some experts pointed out that the results released by the high-end recently showed that the seroconversion rate was 99.8%, and the neutralizing antibody titer was 662.
Shi Xinru, director of the Emerging Virus Research Center of Chang Gung University, said that it is difficult to compare the antibody titers in different laboratories, but the high-end and United Asia are both in the "Chinese Research Institute". However, the titer of Lianya's antibody is only more than 100, which is not high. "It is indeed a pity."
Some analysts said that the results of Phase II of Lianya are in line with expectations, but vaccine stocks have to go for a long time. There are two main points: one is to have big players behind it; the other is the protection of vaccines, especially to cope with more and more complex mutations. Virus, "Lianya and High-end only do Phase III clinical trials to prove that the vaccine is protective."
"United Daily News" commented on the 28th that, strictly speaking, Taiwan's self-produced vaccines have only completed the interim report of the second phase of clinical trials, and the protection of the public is still a question mark.
The authorities have recently announced that they will not restrict people from being vaccinated by brands, but regardless of scientific evidence or public opinion, the people's trust in overseas vaccines is obviously higher.
More importantly, the progress of self-produced vaccines in obtaining international certification has stagnated. It is foreseeable that only when self-produced vaccines become a compelling choice will there be a market.
Judging from the performance of the key players in the green camp, they obviously lack confidence in self-produced vaccines.
Cai Dinggui, the "Taiwan Independence" tycoon and the general convener of the "referendum to protect Taiwan Alliance Promotion Association", recently called on Facebook that Taiwanese should participate in the third phase of clinical trials of the self-produced new crown vaccine.
But he also revealed that he had received two injections of Pfizer vaccine in the United States, which caused controversy.
Some netizens tweeted a passage from Taipei Mayor Ke Wenzhe two years ago, "The sons and grandsons of'Taiwan independence' are hiding in the United States and New Zealand. Liars" and praised Ke Wenzhe as a "prophet."
Some netizens ridiculed, "Professor Tsai really loves Taiwan! Taiwan's local epidemic is serious, so you can go to the United States for vaccinations."
As for Tsai Ing-wen and "Vice President" Lai Qingde, they both claimed to be waiting for the self-produced vaccine. However, senior media person Peng Wenzheng recently broke the news that Tsai Ing-wen had stolen Pfizer vaccine. The arm must be reserved for self-produced vaccines."
In March, after several delays, Taiwan’s "Executive President" Su Zhenchang and the epidemic prevention commander Chen Shizhong finally agreed to vaccinate AstraZeneca, but many people on the island believed that there was fraud and suspected that the two were vaccinating "fake vaccines." .
"Economic Daily" analyzed on the 28th that Taiwan's self-produced vaccines have "three coincidences" on the road to development, which is reminiscent. First, both Uniya and High-end released their data on Sunday, and neither discussed the issue of protection. "That is to say, these two vaccines have no harm to the human body, but can they stop the new coronavirus or mutated virus? No one can now answer this question". The second is that the share prices of the two companies have risen sharply before this. What's more, Taiwan’s "Ministry of Foreign Affairs", the Paraguayan government and the United States-related companies also announced that "Once United Asia obtains Taiwan's emergency authorization, it will purchase 100 The press release of "Wanji" has aroused strong dissatisfaction among Paraguayan people, who questioned why the government should buy this vaccine that has not completed the third phase of testing. The third is that these two companies are inseparable from the United States in the development process. The high-end is to obtain technology from the National Institutes of Health (NIH). In the future, more authorizations will be required to face mutant viruses. "Authorization is to pay for it." , This sum is always a commercial secret and has not been disclosed." As for the connection between Uniasia and the United States, it seems that the questioned Blackwater founder Prince entered the US company Covaxx vaccine distribution plan at the end of last year, and this company is the new company established last year by the founder of Uniasia Biotech Wang Changyi. . According to the article, self-produced vaccines can be strategic products, and Taiwan does need its own vaccine production capacity so that it will not be controlled by others in the future, but the above three coincidences cast a shadow on the development of self-produced vaccines.